Cresemba

Indicated For

aspergillosis, mucormycosis

About This Medication

# CRESEMBA Patient Assistance Program Patient Guide: How to Get Cresemba at Low or No Cost Cresemba (isavuconazonium sulfate) is an antifungal medication used to treat serious invasive fungal infections like invasive aspergillosis and invasive mucormycosis in adults. The **CRESEMBA Patient Assistance Program** from Astellas Pharma provides this medication **at no cost** to eligible uninsured, underinsured, Medicare, or Medicaid patients who meet specific criteria, helping those facing financial barriers access life-saving treatment.[1][6] ## About Cresemba and Why Assistance Matters **Cresemba** is a prescription capsule taken daily to fight dangerous fungal infections that can be life-threatening, especially in people with weakened immune systems. These infections often occur in hospitalized patients or those with conditions like cancer or transplants. Without treatment, they can spread rapidly. The retail cost of Cresemba can exceed thousands of dollars per month, making it unaffordable for many. That's where the Patient Assistance Program steps in—offering free medication shipped directly to your home if you qualify.[1][2][6] This guide explains eligibility, the application process, and next steps in simple terms. Always consult your doctor for medical advice; this program focuses on financial help only. ## Who Qualifies for the Program? The program targets patients with financial need who lack adequate coverage. You may qualify if you are: - **Uninsured** (no prescription insurance at all) - **Underinsured** (insurance doesn't cover enough, leading to high out-of-pocket costs) - **Medicare or Medicaid eligible** (government programs that may not fully cover specialty drugs like Cresemba) **Important notes on income:** Specific income thresholds (like Federal Poverty Level percentages) are not publicly detailed. Eligibility is determined case-by-case by CRESEMBA Support Solutions based on your financial situation, residency, and other factors. No strict income caps are listed, but the focus is on those unable to afford the medication.[1][6] | Household Size | Income Threshold | Notes | |---------------|------------------|-------| | Individual | Not specified | Case-by-case review for uninsured/underinsured[1][6] | | Couple | Not specified | Medicare/Medicaid eligible patients prioritized[6] | | Family of 3 | Not specified | Proof of financial need required | | Family of 4 | Not specified | Contact program for assessment | *Table based on available program details; call 1-800-477-6472 for personalized eligibility check.*[1] ## Insurance Requirements This program is **not** for patients with commercial (private) insurance—that's covered by the separate CRESEMBA Patient Savings Program, which reduces copays to as low as $25 per fill (up to $4,000/year max, no income requirements).[1][4][7] The Patient Assistance Program is specifically for: - Uninsured patients - Underinsured patients - Those on Medicare Part D or Medicaid Government programs like Medicare, Medicaid, VA, TRICARE, or others cannot reimburse claims submitted with assistance from this program. Your healthcare provider and CRESEMBA Support Solutions will verify your coverage during enrollment.[1][2][6] ## Step-by-Step Application Process Applying is straightforward, but your **healthcare provider (HCP)** must initiate it. Here's how: 1. **Get Prescribed:** Discuss Cresemba with your doctor. They must write a prescription for an FDA-approved use (e.g., invasive aspergillosis or mucormycosis).[6][7] 2. **Contact CRESEMBA Support Solutions:** Call **1-800-477-6472** (Mon-Fri, 8 AM-8 PM ET) or visit CRESEMBASupportSolutions.com. Your HCP starts by completing the **Patient Enrollment Form**.[1][3][6] 3. **Gather Documents:** Prepare these required items: - Patient enrollment form (signed by you and HCP) - Proof of residency (e.g., utility bill, driver's license) - Healthcare provider prescription - Insurance information (or proof of no insurance)[6] 4. **Submit Application:** HCP submits via: - Fax: 1-866-317-6235 - Upload through Astellas eService portal - Online at astellaspharmasupportsolutions.com[3][6] Patient must sign the **Patient Authorization Statement** (pages 3-5 of form) allowing info sharing for eligibility and fulfillment.[3] 5. **Approval Notification:** If approved, you and your HCP are notified. Medication ships to your home.[1][6] **Multiple methods available:** Phone, fax, online—choose what works best.[6] ## Timeline and Delivery - **Processing:** 2-5 business days after submission.[6] - **Initial Supply:** 28-day supply shipped free to your home within 2-5 days of approval.[6] - **Refills:** Program contacts your HCP to confirm ongoing need, then calls you to arrange next 28-day shipment. **Reauthorization is required** for continued therapy—your doctor must reconfirm each time.[6] For urgent starts, ask about **CRESEMBA QUICK START+** (one-time 7-day free supply for insured new patients with delays—not for PAP).[7] ## What If You're Denied or Need Alternatives? Denials happen if you don't meet criteria (e.g., commercial insurance eligibility). Options include: - **Switch to Savings Program** if commercially insured (up to $4,000/year copay help).[1][4] - **Appeal:** Contact support at 1-800-477-6472 for review.[1] - **Other Help:** CRESEMBA Support Solutions can refer to independent programs, state assistance, or Partnership for Prescription Assistance.[2][5] - **No biosimilars** available for Cresemba currently. **Persist:** Many denials are reversible with more info. ## Important Disclaimer This guide is for informational purposes based on publicly available program details as of latest updates. Eligibility, terms, and availability can change—**always verify directly with CRESEMBA Support Solutions at 1-800-477-6472**. This is not medical advice; consult your healthcare provider. Astellas reserves the right to modify or end the program. Medication is for the named patient only; do not sell, trade, or seek reimbursement.[1][3][6] (Word count: 1028)

Program information last verified: March 30, 2026